| Danaher–CrestOptics: spinning disk microscopy, 202410– collab integration of Cicero spinning disk unit into Thunder Imager of Leica Microsystems |
2024-10-07 |
| Dynamic Biosensors–Bruker: investment, 202410 acquisition €na of Dynamic Biosensors GmbH + integration in Bruker Biosensors business |
2024-10-02 |
| Immunocore–Danaher: data management software, 202409– supply Genedata SDMS for discovery of TCR therapeutics |
2024-09-05 |
| Alphalytik Pharmaservice–Certania: investment, 202409 acquisition of Alphalytik Pharmaservice GmbH by Certania |
2024-09-04 |
| Irubis–SEVERAL: investment, 202408 financing round pre-Series A led by new investor BioProcess360 Partners |
2024-08-29 |
| Genedata–Danaher: investment, 202408 acquisition of Genedata that will join Danaher’s Life Science segment |
2024-08-19 |
| Bruker–Novalix: drug discovery technology, 202408– strategic collab to enable new paradigms in drug discovery |
2024-08-07 |
| Novalix–Bruker: investment, 202408 strategic minority investment €na by Bruker |
2024-08-07 |
| Thermo Fisher–Biomatter Designs: enzyme design, 202408 supply existent customer Thermo Fisher |
2024-08-05 |
| Agilent–Sigsense Technologies: lab management software, 202407 supply existent Sigsense technology available via Agilent CrossLab Connect |
2024-07-29 |
| Sigsense Technologies–Agilent: investment, 202407 acquisition €na of Sigsense by Agilent |
2024-07-29 |
| Biovectra–Agilent: investment, 202407– acquisition of Biovectra for $925m by Agilent from H.I.G. Capital |
2024-07-22 |
| CytoReason–Thermo Fisher: investment, 202407 financing round totalling $80m incl investor Thermo Fisher Scientific |
2024-07-17 |
| OHMX.bio–Anacura: investment, 202407 acquisition of OHXM.bio by Anacura |
2024-07-04 |
| Enantios–SEVERAL: investment, 202407 seed financing round >CHF1.8m led by Privilège Ventures |
2024-07-01 |
| Leibniz-Gemeinschaft–Bruker: NRM spectrometer, 202406 supply Avance 1.2 GHz NMR system to FMP Berlin-Buch |
2024-06-30 |
| CatSci–Keensight Capital: investment, 202406 additional investment? by Keensight to support acquisition of Reach Separations by CatSci |
2024-06-25 |
| Reach Separations–CatSci: investment, 202406 acqusition of Reach Separations by CatSci Ltd with support from Keensight Capital |
2024-06-25 |
| Sartorius–Nvidia: AI-based drug discovery + manufacturing, 202405– collab expansion incl adaption of Nvidia Clara Suite + DGX platform |
2024-05-16 |
| Sartorius–Sanofi: biopharmaceutical production technology, 202405– collab + license developm of ICB platform to be excl commercialised by Sartorius ww |
2024-05-13 |
| NanoString–Bruker: investment, 202404– acquisition $392.6m of substantially all assets winning bid under Bankruptcy Code |
2024-04-17 |
| IsoSpec Analytics–Another.vc: investment, 202404 pre-seed financing round totalling $1.9m incl co-investor Another.vc |
2024-04-16 |
| IsoSpec Analytics–Founderful: investment, 202404 pre-seed financing round totalling $1.9m incl lead investor Founderful |
2024-04-16 |
| IsoSpec Analytics–SEVERAL: investment, 202404 pre-seed financing round $1.9m led by Founderful |
2024-04-16 |
| IsoSpec Analytics–Tiny.vc: investment, 202404 pre-seed financing round totalling $1.9m incl co-investor Tiny.vc |
2024-04-16 |
| IsoSpec Analytics–Venture Kick: investment, 202404 pre-seed financing round totalling $1.9m incl co-investor Venture Kick |
2024-04-16 |
| NanoString–Patient Square Capital: investment, 202403–202404 stalking horse bid $220m for assets under Bankruptcy Code NOT REALISED |
2024-03-10 |
| Waters–Plasmion: ionisation technology, 202402– collab co-marketing/promotion of SICRIT ion source with Waters Acquity QDa + Select Series Cycli IMS |
2024-02-21 |
| Sysmex–SAFIA Technologies: mycotoxin immunoassays, 202402– distribution ww of tests for food/agri by Sysmex Partec using SAFIA tech + flow cytometry |
2024-02-15 |
| Enable Medicine–KKH Advisors: public relations, 202402 service existent by KKH Advisors |
2024-02-13 |
| Chemspeed–Bruker: investment, 202401– acquisition €na of Chemspeed Technology AG by Bruker |
2024-01-25 |
| Nion–Buker: investment, 202401 acquisition €na of Nion by Bruker |
2024-01-03 |
| LumiraDx–Roche: investment, 202312– acquisition $295m + $55m milestones of parts of LumiraDx Group related to innovative PoC technology |
2023-12-29 |
| Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter |
2023-12-23 |
| Tome Biosciences–Bruker: investment, 202312 financing rounds Series A + B totalling $213m incl investor Bruker Corp |
2023-12-12 |
| Tome Biosciences–SEVERAL: investment, 202312 financing rounds Series A + B $213m announced at launch |
2023-12-12 |
| CatSci–Reach Separations: chromatography, 202311– collab strategic allliance offering method development for small molecule development services |
2023-11-28 |
| Oxford Nanopore–Mérieux: investment, 202310 investment £69.1m purchase of 29m ordinary shares at £2.38/share by bioMérieux |
2023-10-19 |
| Olink–Thermo Fisher: investment, 202310– acquisition cash tender offer $3.1b at $26/share by Thermo Fisher |
2023-10-17 |
| MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker |
2023-10-04 |
| SomaLogic–Standard BioTools: investment, 202310–202401 reverse merger with former SomaCare shareholders owning 57% of combined company |
2023-10-04 |
| Refeyn–Alto Marketing: public relations, 202310 service existent by Alto Marketing Ltd |
2023-10-02 |
| Agilent–Exact Sciences: investment, 202309– acquisition €na of Resolution Bioscience by Exact Sciences from Agilent |
2023-09-12 |
| CrystalsFirst–Helmholtz: drug discovery technology, 202309–202410 collab developm in joint project LigandML with DESY with funding from IFB Hamburg |
2023-09-01 |
| Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash |
2023-08-28 |
| PhenomeX–Bruker: investment, 202308–202310 acquisition cash tender offer $108m by Bruker at $1/share |
2023-08-17 |
| NuChem Sciences–Sygnature Discovery: investment, acquisition of NuChem Sciences by Sygnature Discovery |
2023-07-31 |
| Revvity–Scitara: lab informatics, 202307– collab expansion product integration of Signals Software Suite with DLX technology |
2023-07-27 |
| CrystalsFirst–NexMR: fragment-based drug discovery, 202307– collab combining crystallography technology with NRM for drug discovery |
2023-07-24 |
| Orange Science–Organomation: sample evaporators, 202307– distribution of nitrogen blowdown evaporator lines of Organimation in JP by Orange Science |
2023-07-20 |
| Hema.to–SEVERAL: investment, 202306 seed financing round €3.6m with Elaia Partners + Heal Capital + HTGF |
2023-06-26 |
| Lunaphore–Bio-Techne: investment, 202306– acquisition by of Lunaphore by Bio-Techne ANNOUNCED |
2023-06-22 |
| Ellab–Novo Group: investment, 202306– acquisition of Ellab by Novo Holdings from EQT Private Equity + co-shareholders |
2023-06-21 |
| DNTox–SEVERAL: investment, 202306 seed financing round €1.4m led by HTGF |
2023-06-14 |
| Sartorius–Waters: biopharma production technology, 202306– collab expansion integration of PATROL UPLC PAS with Resolute BioSMB platform |
2023-06-05 |
| Midwest Biosolutions–Bionter: analytical instruments, 202305– collab Midwest Bio to promote + sell Bionter products + services in the US |
2023-05-08 |
| Zontal–Bruker: investment, 202305 acquisition €na of Zontal by Bruker |
2023-05-08 |
| Ten23 Health–Bionter: particle counting, 202305– collab developm of methods incl installation of EVE particle counter at Ten23 Heatlh |
2023-05-02 |
| Bio-Techne–Lunaphore: spatial omics, 202304– collab strategic partnership integrating COMET system with RNAscope technology |
2023-04-17 |
| Mérieux–Oxford Nanopore: nanopore technology, 202304– collab strategic exploring nanopore sequencing for infectious disease diagnostics bioMérieux |
2023-04-14 |
| Agilent–Hamamatsu: digital pathology, 202303– collab distribution of NanoZoomer digital pathology slide scanners by Agilent |
2023-03-10 |
| Agilent–e-MSion: mass spectrometry technology, 2019– collab co-marketing of ExD cell technology with 6500 Series LC-/Q-TOF |
2023-03-09 |
| e-MSion–Agilent: investment, 202303 acquisition of e-MSion by Agilent |
2023-03-09 |
| Agilent–Proscia: digital pathology, 202303– collab ww distribution multi-year for Concentriq Dx platform with Agilent digital pathology solutions |
2023-03-08 |
| Astrea Bioseparations–Biotage: investment, 202302– acquisition $190m in shares + $45 cash milestones of Astrea from Gamma Biosciences (KKR) |
2023-02-15 |
| Biotage–KKR: investment, 202302– investment $25m tog with sale of Astrea Bioseparations by Gamma for shares resulting in 17% share in Biotage of Gamma |
2023-02-15 |
| Wyatt Technology–Waters: investment, 202302–202305 acquisition $1.36b in cash of Wyatt by Waters |
2023-02-15 |
| HEL Group–Zyme Communications: public relations, 202302 service existent by Zyme |
2023-02-08 |
| Danaher–Seed Biosciences: cell dispenser, 202302– distribution excl of DinspenCell in US + Asia + resale in Europe by Molecular Devices |
2023-02-07 |
| SAMDI Tech–Charles River: investment, 202301 acquisition of remaining 80% not already owned for $50m in cash by Charles River |
2023-01-30 |
| Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems |
2023-01-18 |
| Siemens–ASG Superconductors: magnetic resonance imaging, 202301– collab integration of ASG MRI magnets >7T in Siemens Healthineers UFH MRI systems |
2023-01-18 |
| InDevR–Adjuvant Capital: investment, 202301 financing round Series B totalling $9m incl $4m from Adjuvant Capital |
2023-01-17 |
| InDevR–Mérieux: investment, 202301 financing round Series B totalling $9m incl $5m from bioMérieux in connection w partnership |
2023-01-17 |
| InDevR–SEVERAL: investment, 202301 financing round Series B $9m from bioMérieux + Adjuvant Capital |
2023-01-17 |
| Mérieux–InDevR: VaxArray platform, 202301– excl distribution of VaxArray portfolio by bioMérieux in Europe |
2023-01-17 |
| Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea |
2023-01-09 |
| Evosep–Novo Group: investment, 202301 minority investment of $40m by Novo Holdings A/S |
2023-01-09 |
| Acquifer Imaging–Bruker: investment, 202301 acquisition €na of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker |
2023-01-05 |
| Biognosys–Bruker: investment, 202301 acquisition €na of majority share in Biognosys by Bruker |
2023-01-04 |
| Danaher–Advanced Solutions: laboratory automation equipment, 202301 collab developm BAB400 with ImageXpress for 3D Cell Culture + sales by MolDev |
2023-01-04 |
| IsoPlexis–Berkeley Lights: investment, 202212–202303 merger acquisition $57.8m in shares with former Berkeley owners holding 75.2%, renamed PhenomeX |
2022-12-21 |
| Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB |
2022-12-20 |
| Numares–SEVERAL: investment, 202212 financing round €20m from existing investors |
2022-12-20 |
| Variolytics–SEVERAL: investment, 202212 seed financing round €7-digit from HTGF + FTTF + business angels |
2022-12-07 |
| Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices |
2022-12-06 |
| Neurescence–Bruker: investment, 202211–202212 acquisition 100% of Neurescence Inc by Bruker |
2022-11-14 |
| Elemental Machines–SEVERAL: investment, 202211 financing round Series B $41m led by Sageview Capital |
2022-11-10 |
| Inscopix–Bruker: investment, 202211 acquisition €na of Inscopix by Bruker |
2022-11-08 |
| Binding Site–Thermo Fisher: investment, 202210– acquisition £2.25b in cash from shareholder group led by Nordic Capital ANNOUNCED |
2022-10-31 |
| MS-Omics–Clinical Microbiomics: investment, 202210 acquisition of MS-Omics ApS by Clinical Microbiomics A/S |
2022-10-17 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
| Irubis–EU (govt): investment, 202210 seed financing round totalling €2.8m incl co-investor EIC Fund |
2022-10-06 |
| Irubis–High-Tech Gründerfonds: investment, 202210 seed financing round totalling €2.8m incl co-lead investor HTGF |
2022-10-06 |
| Irubis–OTHER: investment, 202210 seed financing round totalling €2.8m incl business angels as co-investors |
2022-10-06 |
| Irubis–SEVERAL: investment, 202210 seed financing round €2.8m led by HTGF + Verve Ventures + Ventura BioMed Investors |
2022-10-06 |
| Irubis–TU Munich: investment, 202210 seed financing round totalling €2.8m incl co-investor Initiative for Industrial Innovators |
2022-10-06 |
| Irubis–Ventura Biomed Investors: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Ventura Biomed Investors |
2022-10-06 |
| Irubis–Verve Capital Partners: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Verve Ventures |
2022-10-06 |
| Agilent–Scitara: lab informatics, 202209– collab product integration of OpenLab CDS + SLIMS with Scientific Integration Platform SIP + DLX |
2022-09-21 |
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spec-capital-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
